Srp Ark Celok Lek
-
Biography Historical Article
[The work of Jovan Andrejević as a medical student in Vienna--his contribution to anatomy and histology].
During the fifties of the 19th century, a Serb from Novi Sad, Jovan Andrejevitsh, was completing his studies at the Medical University in Vienna. Jovan Andrejevitsh was born on November 6, 1833, in Novi Sad. His father was a priest. ⋯ In his first letter, on November 25, 1861, professor Bricke wrote to dr Jovan Andrejevitsh: "... I was very glad to receive good news about you and to hear that you have become Esculap of your home country so quickly. I sent separate copies of your study to all anatomists and physiologists I am keeping in touch with...." From Bricke's second letter, written on July 23, 1862, which was sent to dr Andrejevitsh in Novi Sad, we can see that: "... from the Ferber university book shop in Gissen, I received another 36 copies of your article, and Henley was asking for one of those copies to see that he was wrong in his beliefs." According to professor Bricke this copy of Andrejevitsh's work was sent to several universities in Europe, along with his work "About elementary organisms". (ABSTRACT
-
A very few treatment regimens have shown a benefit in patients with multiple myeloma resistant to conventional melphalan/prednosone therapy or similar combinations. The first "biologically designed" protocol for the treatment of advanced, refractory myeloma was a combination of vincristine, doxorubicin and intermittent high-dose dexamethasone, so called VAD regimen. This report summarizes our experience in VAD regimen in the treatment of advanced, refractory myeloma patients, initially treated with melphalan-based chemotherapy. ⋯ The antitumour effect of VAD regimen originates from a combined effect of doxorubicin and vincristine continuous infusions and intermittent pulses of high-dose corticosteroids. The rationale for protracted administration of vincristine and doxorubicin was based on long generation time and low growth fraction of plasma cells in most patients, while the use of high-dose dexamethasone was based on well-known dose-depend antimyeloma effect of corticosteroids. Using this chemotherapy schedule, significant prolongation of survival was achieved in our responding patients comparing to patients with VAD-resistant myeloma. The major toxic effect of treatment was infection, which was attributed in part to intensive steroid program. Relapse of the disease could be expected about one year after completion of VAD therapy. Nevertheless, the second "plateau-phase" can be obtained upon reinitiation of VAD (ABSTRACT TRUNCATED).